TAMM41

Summary

TAMM41 (TAM41 mitochondrial translocator assembly and maintenance homolog, HGNC:25187) is a protein-coding gene on chromosome 3p25.2, encoding Phosphatidate cytidylyltransferase, mitochondrial (Q96BW9). Catalyzes the conversion of phosphatidic acid (PA) to CDP-diacylglycerol (CDP-DAG), an essential intermediate in the synthesis of phosphatidylglycerol, cardiolipin and phosphatidylinositol. It is a selective cancer dependency (DepMap: 83.4% of cell lines).

Predicted to enable phosphatidate cytidylyltransferase activity. Predicted to be involved in CDP-diacylglycerol biosynthetic process and cardiolipin biosynthetic process. Is active in mitochondrion. Implicated in combined oxidative phosphorylation deficiency 56.

Source: NCBI Gene 132001 — RefSeq curated summary.

At a glance

• Gene–disease (curated): combined oxidative phosphorylation deficiency 56 (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 3
• Clinical variants (ClinVar): 75 total — 4 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 22
• Cancer dependency (DepMap): dependent in 83.4% of screened cell lines
• MANE Select transcript: NM_001284401

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25187
Approved symbol	TAMM41
Name	TAM41 mitochondrial translocator assembly and maintenance homolog
Location	3p25.2
Locus type	gene with protein product
Status	Approved
Aliases	MGC16471, DKFZp434E0519
Ensembl gene	ENSG00000144559
Ensembl biotype	protein_coding
OMIM	614948
Entrez	132001

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 10 protein_coding, 4 nonsense_mediated_decay, 4 retained_intron

ENST00000273037, ENST00000411947, ENST00000414736, ENST00000417723, ENST00000444133, ENST00000455809, ENST00000457498, ENST00000460246, ENST00000486090, ENST00000494388, ENST00000498127, ENST00000630288, ENST00000879036, ENST00000879037, ENST00000937105, ENST00000937106, ENST00000937107, ENST00000937108

RefSeq mRNA: 6 — MANE Select: NM_001284401 NM_001284401, NM_001321294, NM_001321295, NM_001366031, NM_001394474, NM_138807

CCDS: CCDS2607, CCDS68345, CCDS93211

Canonical transcript exons

ENST00000455809 — 8 exons

Exon	Start	End
ENSE00001782172	11846502	11846885
ENSE00003507905	11839222	11839314
ENSE00003532497	11817192	11817337
ENSE00003563466	11844029	11844211
ENSE00003564046	11790442	11790581
ENSE00003613210	11809517	11809682
ENSE00003667651	11829714	11829864
ENSE00003671197	11807833	11807895

Expression profiles

Bgee: expression breadth ubiquitous, 136 present calls, max score 91.79.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 25.5609 / max 352.0826, expressed in 1802 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
41111	25.5609	1802

Top tissues by expression

138 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.79	gold quality
granulocyte	CL:0000094	87.00	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.77	gold quality
ovary	UBERON:0000992	86.18	gold quality
left ovary	UBERON:0002119	86.14	gold quality
right ovary	UBERON:0002118	85.70	gold quality
skin of abdomen	UBERON:0001416	85.66	gold quality
zone of skin	UBERON:0000014	85.56	gold quality
skin of leg	UBERON:0001511	85.50	gold quality
tonsil	UBERON:0002372	85.42	gold quality
uterine cervix	UBERON:0000002	85.03	gold quality
tibial nerve	UBERON:0001323	85.03	gold quality
thoracic mammary gland	UBERON:0005200	84.52	gold quality
endocervix	UBERON:0000458	84.35	gold quality
vagina	UBERON:0000996	84.12	gold quality
lymph node	UBERON:0000029	84.07	gold quality
body of pancreas	UBERON:0001150	84.03	gold quality
esophagus mucosa	UBERON:0002469	84.03	gold quality
endometrium	UBERON:0001295	83.93	gold quality
body of uterus	UBERON:0009853	83.78	gold quality
colonic epithelium	UBERON:0000397	83.73	gold quality
ectocervix	UBERON:0012249	83.71	gold quality
calcaneal tendon	UBERON:0003701	83.49	gold quality
sural nerve	UBERON:0015488	83.49	gold quality
subcutaneous adipose tissue	UBERON:0002190	83.46	gold quality
spleen	UBERON:0002106	83.44	gold quality
lower esophagus mucosa	UBERON:0035834	83.34	gold quality
myometrium	UBERON:0001296	83.31	gold quality
urinary bladder	UBERON:0001255	83.29	gold quality
mucosa of transverse colon	UBERON:0004991	83.28	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.50

Regulation

Is transcription factor: no

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 83.4% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 1)

• Association of mitochondrial variants and haplogroups identified by whole exome sequencing with Alzheimer’s disease. (PMID:34152079)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tamm41	ENSDARG00000100157
mus_musculus	Tamm41	ENSMUSG00000030316
rattus_norvegicus	Tamm41	ENSRNOG00000007874
drosophila_melanogaster	CG33331	FBGN0067628
caenorhabditis_elegans	Y71F9B.2	WBGENE00022126

Protein

Protein identifiers

Phosphatidate cytidylyltransferase, mitochondrial — Q96BW9 (reviewed: Q96BW9)

Alternative names: CDP-diacylglycerol synthase, Mitochondrial translocator assembly and maintenance protein 41 homolog

All UniProt accessions (4): Q96BW9, B4E101, G3V0F3, H7C1A2

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the conversion of phosphatidic acid (PA) to CDP-diacylglycerol (CDP-DAG), an essential intermediate in the synthesis of phosphatidylglycerol, cardiolipin and phosphatidylinositol.

Subcellular location. Mitochondrion inner membrane.

Disease relevance. Combined oxidative phosphorylation deficiency 56 (COXPD56) [MIM:620139] An autosomal recessive mitochondrial disease characterized by lethargy at birth, hypotonia, developmental delay, myopathy, and ptosis. The disease may be caused by variants affecting the gene represented in this entry.

Pathway. Phospholipid metabolism; CDP-diacylglycerol biosynthesis; CDP-diacylglycerol from sn-glycerol 3-phosphate: step 3/3.

Similarity. Belongs to the TAM41 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q96BW9-1	1	yes
Q96BW9-2	2
Q96BW9-3	3

RefSeq proteins (6): NP_001271330, NP_001308223, NP_001308224, NP_001352960, NP_001381403, NP_620162 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR015222	Tam41	Family

Pfam: PF09139

Catalyzed reactions (Rhea), 1 shown:

• a 1,2-diacyl-sn-glycero-3-phosphate + CTP + H(+) = a CDP-1,2-diacyl-sn-glycerol + diphosphate (RHEA:16229)

UniProt features (10 total): sequence variant 5, splice variant 4, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96BW9-F1	73.42	0.50

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 132 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_UP, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_PHOSPHATIDYLGLYCEROL_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_PHOSPHOLIPID_BIOSYNTHETIC_PROCESS, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, GOCC_MITOCHONDRIAL_ENVELOPE, GOBP_GLYCEROLIPID_BIOSYNTHETIC_PROCESS, GOBP_GLYCEROPHOSPHOLIPID_METABOLIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_LIPID_BIOSYNTHETIC_PROCESS, GOBP_CARDIOLIPIN_METABOLIC_PROCESS, POU3F2_02, IVANOVA_HEMATOPOIESIS_INTERMEDIATE_PROGENITOR

GO Biological Process (4): CDP-diacylglycerol biosynthetic process (GO:0016024), cardiolipin biosynthetic process (GO:0032049), lipid metabolic process (GO:0006629), phospholipid biosynthetic process (GO:0008654)

GO Molecular Function (4): phosphatidate cytidylyltransferase activity (GO:0004605), protein binding (GO:0005515), transferase activity (GO:0016740), nucleotidyltransferase activity (GO:0016779)

GO Cellular Component (4): mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), mitochondrial matrix (GO:0005759), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
CDP-diacylglycerol metabolic process	1
glycerophospholipid biosynthetic process	1
phosphatidylglycerol biosynthetic process	1
cardiolipin metabolic process	1
primary metabolic process	1
phospholipid metabolic process	1
lipid biosynthetic process	1
organophosphate biosynthetic process	1
cytidylyltransferase activity	1
binding	1
catalytic activity	1
transferase activity, transferring phosphorus-containing groups	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
mitochondrion	1
intracellular organelle lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

726 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TAMM41	CDS1	Q92903	985
TAMM41	CDS2	O95674	983
TAMM41	CDIPT	O14735	962
TAMM41	PTPMT1	Q8WUK0	772
TAMM41	TAFAZZIN	Q16635	722
TAMM41	PGS1	Q32NB8	710
TAMM41	PRELID1	Q9Y255	691
TAMM41	TRIAP1	O43715	689
TAMM41	CRLS1	Q9UJA2	628
TAMM41	MBOAT2	Q6ZWT7	600
TAMM41	PITPNM1	O00562	562
TAMM41	PISD	Q9UG56	542
TAMM41	AGK	Q53H12	539
TAMM41	LCLAT1	Q6UWP7	527
TAMM41	CEPT1	Q9Y6K0	506

IntAct

64 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
TNFSF14	TMEM11	psi-mi:“MI:0914”(association)	0.670
TNFSF8	TOR1B	psi-mi:“MI:0914”(association)	0.640
FAM174A	BLTP3B	psi-mi:“MI:0914”(association)	0.530
LPAR4	POTEF	psi-mi:“MI:0914”(association)	0.530
SLC15A1	METTL15	psi-mi:“MI:0914”(association)	0.530
SLC2A12	METTL15	psi-mi:“MI:0914”(association)	0.530
LAMP3	METTL15	psi-mi:“MI:0914”(association)	0.530
APBA3	DUSP11	psi-mi:“MI:0914”(association)	0.530
TMEM9	ESYT2	psi-mi:“MI:0914”(association)	0.530
CD70	METTL15	psi-mi:“MI:0914”(association)	0.530
TAMM41	BCKDHA	psi-mi:“MI:0915”(physical association)	0.400
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
CD70	GXYLT2	psi-mi:“MI:0914”(association)	0.350
LAMP2	HSPA12A	psi-mi:“MI:0914”(association)	0.350
APBB1	HERC2	psi-mi:“MI:0914”(association)	0.350
TNFSF8	NME4	psi-mi:“MI:0914”(association)	0.350
NMES1	NDUFS8	psi-mi:“MI:0914”(association)	0.350
MIX23	TAMM41	psi-mi:“MI:0914”(association)	0.350
COQ9	NDUFS8	psi-mi:“MI:0914”(association)	0.350
NDUFA4	NUDT19	psi-mi:“MI:0914”(association)	0.350

BioGRID (79): TAMM41 (Affinity Capture-MS), TAMM41 (Affinity Capture-MS), TAMM41 (Affinity Capture-MS), TAMM41 (Affinity Capture-MS), TAMM41 (Affinity Capture-MS), GPI (Affinity Capture-MS), PMPCB (Affinity Capture-MS), ECH1 (Affinity Capture-MS), TAMM41 (Affinity Capture-MS), TAMM41 (Affinity Capture-MS), TAMM41 (Affinity Capture-MS), TAMM41 (Affinity Capture-MS), TAMM41 (Affinity Capture-MS), TAMM41 (Affinity Capture-MS), TAMM41 (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4IXF6, A1XQS2, B0UYT5, B4PQ50, F1M7L9, F4I4P8, F6QZ15, M0R2J8, O09111, O14548, O60397, O82067, P0CU26, P34660, Q0MQJ3, Q0MQJ4, Q0MQJ5, Q1LUC3, Q2KI08, Q3SYY7, Q3T061, Q4QQV3, Q4R6H1, Q56VL3, Q5REP2, Q5XTS1, Q61387, Q6DQX6, Q6GL38, Q7SXI1, Q8BGY7, Q8HXG5, Q8WWI1, Q92830, Q92831, Q95JR3, Q96BW9, Q96P26, Q96Q45, Q99KD6

Diamond homologs: D3ZKT0, O74339, P53230, Q32L81, Q3B7H2, Q3TUH1, Q550P4, Q61X59, Q6DJM2, Q8INF2, Q96BW9, Q9N4G7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

75 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	1
Uncertain significance	49
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
1299473	NM_001284401.2(TAMM41):c.329A>G (p.Tyr110Cys)	Pathogenic
1299474	NM_001284401.2(TAMM41):c.806dup (p.Asn269fs)	Pathogenic
1800463	NM_001284401.2(TAMM41):c.410C>T (p.Pro137Leu)	Pathogenic
1800464	NM_001284401.2(TAMM41):c.709-2A>G	Pathogenic
3775079	NM_001284401.2(TAMM41):c.709-3C>A	Likely pathogenic

SpliceAI

1464 predictions. Top by Δscore:

Variant	Effect	Δscore
3:11809513:GTACC:G	donor_loss	1.0000
3:11809514:TACCT:T	donor_loss	1.0000
3:11809515:A:AC	donor_gain	1.0000
3:11809515:A:AG	donor_loss	1.0000
3:11809516:C:CC	donor_gain	1.0000
3:11809679:CTAT:C	acceptor_gain	1.0000
3:11809680:TAT:T	acceptor_gain	1.0000
3:11809681:AT:A	acceptor_gain	1.0000
3:11809683:C:CC	acceptor_gain	1.0000
3:11809683:CT:C	acceptor_loss	1.0000
3:11829710:TAA:T	donor_loss	1.0000
3:11829711:AAC:A	donor_loss	1.0000
3:11829712:A:T	donor_loss	1.0000
3:11829864:CCT:C	acceptor_loss	1.0000
3:11829865:C:CC	acceptor_gain	1.0000
3:11829865:CTG:C	acceptor_loss	1.0000
3:11829866:T:C	acceptor_loss	1.0000
3:11832996:T:TA	donor_gain	1.0000
3:11833001:A:AC	donor_gain	1.0000
3:11833002:C:CC	donor_gain	1.0000
3:11833002:CT:C	donor_gain	1.0000
3:11833005:A:AC	donor_gain	1.0000
3:11833006:A:C	donor_gain	1.0000
3:11839214:ACACT:A	donor_loss	1.0000
3:11839215:CACT:C	donor_loss	1.0000
3:11839216:ACTCA:A	donor_loss	1.0000
3:11839217:CTCAC:C	donor_loss	1.0000
3:11839218:TCA:T	donor_loss	1.0000
3:11839219:CA:C	donor_loss	1.0000
3:11839220:A:AC	donor_gain	1.0000

AlphaMissense

2209 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:11839260:A:G	W125R	0.997
3:11839260:A:T	W125R	0.997
3:11809552:G:T	A280D	0.995
3:11809648:A:G	L248P	0.993
3:11839268:A:G	L122P	0.993
3:11839258:C:A	W125C	0.990
3:11839258:C:G	W125C	0.990
3:11809553:C:G	A280P	0.986
3:11829746:A:G	L177P	0.986
3:11829808:A:C	N156K	0.986
3:11829808:A:T	N156K	0.986
3:11839232:A:G	L134P	0.986
3:11839241:G:T	A131D	0.986
3:11829798:C:G	A160P	0.984
3:11829797:G:T	A160D	0.981
3:11844166:A:G	W61R	0.981
3:11844166:A:T	W61R	0.981
3:11839259:C:G	W125S	0.980
3:11839307:T:A	K109I	0.980
3:11817265:A:G	F212S	0.978
3:11844152:G:C	N65K	0.978
3:11844152:G:T	N65K	0.978
3:11829806:A:G	L157P	0.973
3:11829785:G:T	A164D	0.972
3:11829786:C:G	A164P	0.972
3:11839259:C:A	W125L	0.972
3:11839226:T:A	K136I	0.971
3:11839235:C:G	R133P	0.971
3:11809636:G:C	P252R	0.970
3:11809636:G:T	P252H	0.970

dbSNP variants (sampled 300 via entrez): RS1000005940 (3:11826493 C>T), RS1000040520 (3:11806345 A>G), RS1000049683 (3:11791942 G>A), RS1000057109 (3:11757458 C>T), RS1000058378 (3:11766355 C>T), RS1000104647 (3:11800899 A>G), RS1000161125 (3:11765115 C>A), RS1000166682 (3:11801556 G>A), RS1000177037 (3:11822453 A>C), RS1000192843 (3:11741997 A>G), RS1000206580 (3:11822764 A>C), RS1000265063 (3:11759838 G>A), RS1000279256 (3:11735501 G>T), RS1000280727 (3:11722417 C>T), RS1000296825 (3:11769376 G>T)

Disease associations

OMIM: gene MIM:614948 | disease phenotypes: MIM:609060, MIM:620139

GenCC curated gene-disease

Disease	Classification	Inheritance
combined oxidative phosphorylation deficiency 56	Strong	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
mitochondrial disease	Moderate	AR

Mondo (3): combined oxidative phosphorylation deficiency (MONDO:0000732), combined oxidative phosphorylation deficiency 56 (MONDO:0859323), respiratory failure (MONDO:0021113)

Orphanet (0):

HPO phenotypes

22 total (22 of 22 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000508	Ptosis
HP:0000590	Progressive external ophthalmoplegia
HP:0001252	Hypotonia
HP:0001254	Lethargy
HP:0001263	Global developmental delay
HP:0001284	Areflexia
HP:0001508	Failure to thrive
HP:0002015	Dysphagia
HP:0002194	Delayed gross motor development
HP:0002878	Respiratory failure
HP:0002919	Ketonuria
HP:0003236	Elevated circulating creatine kinase concentration
HP:0003557	Increased variability in muscle fiber diameter
HP:0003577	Congenital onset
HP:0003648	Lacticaciduria
HP:0003701	Proximal muscle weakness
HP:0003803	Type 1 muscle fiber predominance
HP:0008347	Decreased activity of mitochondrial complex IV
HP:0011923	Decreased activity of mitochondrial complex I
HP:0011924	Decreased activity of mitochondrial complex III
HP:0012120	Methylmalonic aciduria

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST000977_1	Alcohol dependence	4.000000e-07
GCST009281_1	Microalbuminuria in type 1 diabetes	8.000000e-10
GCST90006920_1	Herpes simplex virus 2 mgG-1 antibody levels	2.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009350	Anti-herpes simplex virus 2 IgG measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D012131	Respiratory Insufficiency	C08.618.846

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression	2
Particulate Matter	affects cotreatment, decreases expression, increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
bicalutamide	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
NSC 689534	decreases expression, affects binding	1
Acetaminophen	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Copper	affects binding, decreases expression	1
Doxorubicin	decreases expression	1
Gasoline	decreases expression, increases abundance, affects cotreatment	1
Ivermectin	decreases expression	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, decreases expression, increases abundance	1
Rotenone	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Aflatoxin B1	increases expression	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00208078	PHASE4	TERMINATED	Effect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure.
NCT00291460	PHASE4	UNKNOWN	Inspiratory Muscle Training in Hypercapnic COPD
NCT00355732	PHASE4	COMPLETED	Chronic Obstructive Pulmonary Disease and Weaning From Mechanical Ventilation in Difficult to Wean Patients
NCT00560287	PHASE4	UNKNOWN	Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis
NCT00600639	PHASE4	TERMINATED	Non-Invasive Mechanical Ventilation in Elderly Patients
NCT00698958	PHASE4	COMPLETED	Ambulatory Adaptation to Non-Invasive Mechanical Ventilation
NCT00708149	PHASE4	COMPLETED	Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial
NCT00732537	PHASE4	COMPLETED	Inhaled Nitric Oxide by Oxygen Hood in Neonates
NCT00925860	PHASE4	COMPLETED	Non-Positive Pressure Ventilation in Hypoxemic Patients
NCT01204281	PHASE4	COMPLETED	Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients
NCT01280019	PHASE4	UNKNOWN	FRC Guided Therapy in Acute Respiratory Failure
NCT01472302	PHASE4	COMPLETED	Closed Loop Ventilation Strategy in Intensive Care Unit (ICU) Patients
NCT01572337	PHASE4	COMPLETED	Early Non-invasive Ventilation Outside the Intensive Care Unit
NCT01941524	PHASE4	COMPLETED	Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations
NCT02203019	PHASE4	COMPLETED	Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure
NCT02491346	PHASE4	UNKNOWN	A Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU
NCT02497729	PHASE4	COMPLETED	Checklists and Upright Positioning in Endotracheal Intubation of Critically Ill Patients (Check-UP) Trial
NCT02526862	PHASE4	COMPLETED	Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation
NCT02958150	PHASE4	UNKNOWN	Dexmedetomidine Versus Standard Clinical Practice During Non Invasive Mechanical Ventilation
NCT03026777	PHASE4	COMPLETED	Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation
NCT03337373	PHASE4	COMPLETED	The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium
NCT03625687	PHASE4	TERMINATED	Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant
NCT03787732	PHASE4	COMPLETED	Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation
NCT03962725	PHASE4	TERMINATED	Avoiding Neuromuscular Blockers to Reduce Complications
NCT04092621	PHASE4	UNKNOWN	Rapid Atrial Fibrillation Treatment Strategy
NCT04350086	PHASE4	WITHDRAWN	Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection
NCT04496362	PHASE4	ACTIVE_NOT_RECRUITING	Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study
NCT05277896	PHASE4	COMPLETED	Randomized Trial of Sedative Choice for Intubation
NCT05322447	PHASE4	COMPLETED	High-dose L-Carnitine and Diaphragmatic Function Assessed by Ultrasonography in Patients With Respiratory Failure.
NCT05843123	PHASE4	COMPLETED	Comparison of Gas Exchange Between Two Invasive Mechanical Ventilation Modes in Children
NCT06401083	PHASE4	RECRUITING	The Effect of an Additional Pre-extubational Loading Dose of Caffeine-citrate
NCT06881927	PHASE4	NOT_YET_RECRUITING	Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
NCT00000562	PHASE3	COMPLETED	Extracorporeal Support for Respiratory Insufficiency (ECMO)
NCT00148642	PHASE3	COMPLETED	Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)
NCT00221520	PHASE3	UNKNOWN	Sedation in the Intensive Care Unit
NCT00230984	PHASE3	COMPLETED	IRAD2 : Patients With Respiratory Failure at Home
NCT00248443	PHASE3	COMPLETED	Réa-MiniMax: Severe Acute Respiratory Failure in Hematology and Cancer Patients Without Bronchoalveolar Lavage
NCT00347321	PHASE3	COMPLETED	Early Percutaneous Tracheostomy for Cardiac Surgery (ETOC)
NCT00549809	PHASE3	COMPLETED	Comparison Between IMV and SIMV/PS for Ventilatory Support of Children: a Randomized Clinical Trial
NCT01076816	PHASE3	TERMINATED	Dexmedetomidine Pharmacokinetics-pharmacodynamics in Mechanically Ventilated Children With Single-organ Respiratory Failure